NCT03342911View on ClinicalTrials.gov

Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

November 13, 2017

Primary Completion Date

October 6, 2020

Study Completion Date

October 6, 2020

Conditions
Name Human Papillomavirus Positive Oropharyngeal Squamous Cell CarcinomaStage II Oropharyngeal Squamous Cell CarcinomaStage III Hypopharyngeal Squamous Cell CarcinomaStage III Laryngeal Squamous Cell CarcinomaStage III Oral Cavity Squamous Cell CarcinomaStage III Oropharyngeal Squamous Cell CarcinomaStage IV Hypopharyngeal Squamous Cell CarcinomaStage IV Laryngeal Squamous Cell CarcinomaStage IV Oral Cavity Squamous Cell CarcinomaStage IV Oropharyngeal Squamous Cell CarcinomaStage IVA Hypopharyngeal Squamous Cell CarcinomaStage IVA Laryngeal Squamous Cell CarcinomaStage IVA Oral Cavity Squamous Cell CarcinomaStage IVA Oropharyngeal Squamous Cell CarcinomaStage IVB Hypopharyngeal Squamous Cell CarcinomaStage IVB Laryngeal Squamous Cell CarcinomaStage IVB Oral Cavity Squamous Cell CarcinomaStage IVB Oropharyngeal Squamous Cell CarcinomaStage IVC Hypopharyngeal Squamous Cell CarcinomaStage IVC Laryngeal Squamous Cell CarcinomaStage IVC Oral Cavity Squamous Cell CarcinomaStage IVC Oropharyngeal Squamous Cell Carcinoma
Interventions
DRUG

Paclitaxel

Given IV

DRUG

Carboplatin

Given IV

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (3)

19001

Abington- Jefferson Health, Abington

19107

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

19111

Fox Chase Cancer Center, Philadelphia

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER